Idaho Medicaid does not cover Wegovy or Zepbound for weight loss

Idaho Medicaid's rules exclude drugs used to treat obesity from coverage, so it does not pay for Wegovy, Zepbound, Wegovy tablets, Foundayo or Saxenda for weight loss. None of these drugs appears on the Idaho Medicaid preferred drug list effective July 1, 2026.453

Idaho Medicaid has no prior authorization path for GLP-1s used for weight loss. Its diabetes GLP-1 class uses a diagnosis check for preferred drugs and the general preferred drug list rules for non-preferred drugs.12

• Preferred diabetes GLP-1s (Ozempic pen, Trulicity, Victoza): an ICD-10 diagnosis of type 2 diabetes in the member's Idaho Medicaid record or submitted with the pharmacy claim.
• Non-preferred drugs (such as Mounjaro or the Ozempic tablet): a failed adequate trial of at least two preferred drugs, or a contraindication to starting with a preferred drug, plus documented medical necessity beyond convenience.
• Samples, patient assistance or self-pay use do not count when a prior authorization request is reviewed.

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no Idaho Department of Health and Welfare announcement that Idaho has joined.7

The State of Idaho health plan stopped covering all medications prescribed for weight loss on Nov. 1, 2025, naming Wegovy, Saxenda and Zepbound; GLP-1s prescribed for diabetes are still covered. The plan booklet for the year that began July 1, 2026, still excludes prescription medications meant for weight reduction, except as included on the plan's drug list.891011

Pharmacy benefit: Regence BlueShield of Idaho (medical and prescription drug benefits).

Marketplace (ACA) plans: Idaho's essential health benefits benchmark plan for 2025 to 2027, a Blue Cross of Idaho Preferred Blue small-group PPO, excludes any prescription drug prescribed mainly to help with weight loss.1516

On the Idaho Medicaid preferred drug list effective July 1, 2026 (last revised Sept. 1, 2026), the Ozempic pen, Trulicity and Victoza are preferred, and Mounjaro, the Ozempic tablet, Bydureon BCise, Byetta and generic exenatide and liraglutide are non-preferred. A preferred GLP-1 needs a type 2 diabetes diagnosis code in the member's record or on the pharmacy claim.13

In 2025, Idaho Medicaid paid for 45,851 GLP-1 prescriptions, $46.0 million before rebates: 23 per 1,000 residents, against 32 across the states and DC, 27th of 51.64 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 6 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.3940303126341929

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2627281934353637383332
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.212319

In 2024, Medicare Part D drug plans paid for 118,560 GLP-1 claims from prescribers in Idaho, $140.0 million in total drug cost.65

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.69 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Idaho on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7071 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

We found no action on compounded GLP-1s by Idaho’s board of pharmacy or attorney general on their own sites.17

The FDA’s register lists 0 outsourcing facilities (503B) in Idaho, as of November 6, 2026.66